Tucatinib Active Regardless of Hormone Receptor Status

(MedPage Today) -- The pivotal HER2CLIMB trial showed that the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine (Xeloda) resulted in clinically meaningful improvements in overall survival (OS), progression-free survival...